Is There Strength Behind the Numbers For NovaBay Pharmaceuticals, Inc. (AMEX:NBY)

The Value Composite Two of NovaBay Pharmaceuticals, Inc. (AMEX:NBY) is 97. The VC2 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, price to earnings and shareholder yield.  Similarly, the Value Composite One (VC1) is a method that investors use to determine a company’s value.  The VC1 of NovaBay Pharmaceuticals, Inc. (AMEX:NBY) is 94.  A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company.  The VC1 is calculated using the same metrics as VC2, but without taking into consideration shareholder yield.

Investors often have to make the decision of how aggressive they are going to invest. Some investors looking to make a quick dollar may jump in head first without a plan. This can be dangerous for the health of the portfolio in the long-term. Taking a chance on a risky stock may provide high returns, but investors often need to calculate whether the risk is worth the reward. Managing that risk in turbulent markets may help keep the average investor afloat when the markets inevitably turn sour for an extended period. Doing all the necessary stock research may include keeping a close tab on technicals, fundamentals, relevant economic data, and earnings reports. Investors may have to find a way to keep the rational side from being consumed by irrational behavior when studying the markets.

We can now take a quick look at some historical stock price index data. NovaBay Pharmaceuticals, Inc. (AMEX:NBY) presently has a 10 month price index of 1.05976. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 0.86900, the 24 month is 0.91474, and the 36 month is 0.23329. Narrowing in a bit closer, the 5 month price index is 1.60926, the 3 month is 0.94457, and the 1 month is currently 0.95495.

Watching some historical volatility numbers on shares of NovaBay Pharmaceuticals, Inc. (AMEX:NBY), we can see that the 12 month volatility is presently 62.115000. The 6 month volatility is 62.858200, and the 3 month is spotted at 44.191200. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period. 

Valuation Scores

Shifting gears, we can see that NovaBay Pharmaceuticals, Inc. (AMEX:NBY) has a Q.i. Value of 88.00000. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be.

At the time of writing, NovaBay Pharmaceuticals, Inc. (AMEX:NBY) has a Piotroski F-Score of 6. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

NovaBay Pharmaceuticals, Inc. has an M-score Beneish of -0.324793. This M-score model was developed by Messod Beneish in order to detect manipulation of financial statements. The score uses a combination of eight different variables. The specifics of the variables and formula can be found in the Beneish paper “The Detection of Earnings Manipulation”.

Investors may be interested in viewing the Gross Margin score on shares of NovaBay Pharmaceuticals, Inc. (AMEX:NBY). The name currently has a score of 2.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative.

NovaBay Pharmaceuticals, Inc. (AMEX:NBY) has a current MF Rank of 15862. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks. NovaBay Pharmaceuticals, Inc. has a current ERP5 Rank of 16431. The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.

Leave A Reply

Your email address will not be published.